Objective: To investigate the consistency between pathologic immunohistochemistry assay and flow immunotyping of patients with lymphoma cell leukemia.
Methods: The immunohistochemistry and flow immunotyping data of 31 patients with non-hodgkin lymphoma admitted in our hospital from January 2012 to December 2018 were analyzed retrospectively. The pathologic immunohistochemical expression of lymphatic cells was compared with that of flow immunotyping types, and the change of expression rate of various antigens in the progression of lymphomas into leukemia stage was studied. The characteristics of immune typing and pathologic immunohistochemistry of lymphoblastic leukemia, and their diagnostic value in lymphoblastic leukemia was observed.
Results: All patients with lymphoma reached the leukemia stage. The results of flow immunotyping were basically consistent with the results of pathological immunohistochemistry. The pathological immunohistochemistry showed that CD5, CD3, CD99, CD7, CD34, CD43, etc. mainly expressed in the patients with T lymphocyte lymphoma leukemia, of which CD5 showed the highest expression rate and its positive rate was 100%. The flow immunotyping showed that CD7, CD3, CD2, CD5, CD11b, CD34 and HLA-DR was mainly expressed in the patients with T lymphocyte lymphoma leukemia, of which CD7 was the most sensitive and its positive rate was 100 %. Although the antigens expressed in the pathologic immunohistochemistry and flow immunotyping were basically consistent, there were differences in the expression rates of various antigens, CD20, CD79a, BCL-2, CD10, and the Hodgkin's lymphoma cell antigen PAX5 derived from B cells them mainly expressed in BLL patients assay by pathological immunohistochemistry, among the expression rate of CD20 was 100%, which was higher than other antigen expression rate. CD19, CD20, CD22, CD79a, skappa, and early antigen HLA-DR mainly expressed in BLL patients assayed by flow immunotyping, among them CD19 showed a positive rate of 94.7%. The results of immunohistochemistry and flow immunotyping were compared, it was found that 42% of the patients were accompanied by CD20 expression loss, and the survival period of these patients was significantly reduced.
Conclusion: 25% of patients with T-lymphoma leukemia are accompanied by CD3 expression loss, and 42% of patients with B-cell lymphoma leukemia are accompanied by CD20 expression loss. There is no significant change in survival of T-cell lymphoma leukemia patients with CD3 expression loss, however, the survival period of B-cell lymphoma leukemia patients with CD20 expression loss is significantly shortened.
题目: 淋巴瘤细胞白血病患者病理免疫组化及骨髓流式免疫分型结果对比及临床指导意义.
目的: 探讨淋巴瘤细胞白血病患者病理免疫组化结果与骨髓流式免疫分型结果的一致性.
方法: 回顾性分析2012年1月至2018年12月本院收治的31例非霍奇金淋巴瘤细胞白血病患者的病理免疫组化与骨髓免疫分型资料, 对淋巴瘤细胞的病理免疫组化各抗原与流式免疫分型各抗原表达情况进行对比, 了解淋巴瘤在进展到白血病期瘤细胞各个抗原表达率的变化情况。观察淋巴瘤细胞白血病患者病理免疫组化和骨髓流式免疫分型特点以及二者在淋巴瘤细胞白血病的诊断价值.
结果: 所有淋巴瘤均达到白血病期, 流式免疫分型结果与病理免疫组化结果基本一致。T淋巴瘤细胞白血病患者的病理免疫组化显示, 主要表达CD5、CD3、CD99、CD7、CD34、CD43等, 其中CD5的表达率最高, 其阳性率为100%; T淋巴瘤细胞白血病患者的流式免疫分型显示, 主要表达CD7、CD3、CD2、CD5、CD11b、CD34及HLA-DR, 其中CD7最为敏感, 其阳性率为100%。T淋巴瘤细胞虽然在病理免疫组化和流式免疫分型中表达的抗原较为一致, 但在不同抗原的表达率上存在差异。B细胞淋巴瘤白血病患者的病理免疫组化显示, 主要表达CD20、CD79a、BCL-2、CD10以及B细胞来源的霍奇金淋巴瘤细胞抗原PAX5等, 其中CD20表达率为100%, 高于其他抗原的表达率; B淋巴瘤细胞白血病患者免疫分型显示, 主要表达CD19、CD20、CD22、CD79a、skappa及早期抗原HLA-DR等, 其中CD19阳性率最高为94.7%。对比病理免疫组化和流式免疫分型的抗原表达结果, 42%的患者伴CD20表达缺失, 该类患者生存期显著缩短.
结论: T淋巴瘤细胞白血病患者中25%的患者伴随CD3的表达缺失, B细胞淋巴瘤白血病患者中42%的患者伴随CD20表达缺失。CD3表达缺失的T细胞淋巴瘤白血病患者的生存期无明显变化, 而CD20表达缺失的B细胞淋巴瘤白血病患者的生存期明显缩短.